Neogen Divests Genomics Business to Zoetis in $160 Million Strategic Deal

Neogen Corporation, a leading food safety solutions provider, announced this week that it has reached an agreement to transfer its genomics business to Zoetis Inc., a prominent animal health company, in a transaction valued at $160 million. This strategic move reflects Neogen’s effort to refocus operations on its core competencies and streamline its business portfolio.

Transaction Details and Timeline

The proposed divestiture represents a planned initiative to consolidate resources and concentrate on the company’s primary market segments. Neogen’s genomics business, which generated approximately $90 million in revenue during fiscal year 2025, will become part of Zoetis’s expanding portfolio. The transaction is anticipated to reach completion by the end of H1 2027, pending customary closing conditions.

According to Neogen’s official statement, proceeds derived from this sale will be primarily allocated toward reducing the company’s debt obligations. This financial strategy underscores management’s commitment to strengthening the balance sheet while maintaining operational focus.

Strategic Restructuring and Financial Impact

The genomics divestiture aligns with Neogen’s broader strategy to simplify operations and concentrate capital on core strategic markets. By transferring the genomics business—a sector that, while profitable, sits outside the company’s primary food safety focus—management aims to enhance operational efficiency and shareholder value creation.

From a financial perspective, this move should provide meaningful debt reduction capacity. The transaction demonstrates a disciplined approach to portfolio management, allowing Neogen to redirect resources toward higher-margin opportunities within its core food safety division.

Market Response

Trading on the Nasdaq under ticker NEOG, Neogen shares showed modest downward momentum in pre-market trading at $11.20, reflecting a 0.27% decline. This measured market reaction suggests investors are evaluating the long-term strategic benefits of the portfolio optimization against near-term revenue considerations.

The successful completion of this genomics business transfer to Zoetis will mark a significant milestone in Neogen’s transformation toward a more focused, operationally efficient organization.